Literature DB >> 11673596

Fish oil supplementation improves visual evoked potentials in children with phenylketonuria.

S Beblo1, H Reinhardt, A C Muntau, W Mueller-Felber, A A Roscher, B Koletzko.   

Abstract

Visual evoked potentials (VEP) were measured in 36 patients with early-treated phenylketonuria (PKU; aged 1 to 11 years) and good metabolic control before and after supplementation with omega-3 long-chain polyunsaturated fatty acids (LC-PUFA) from fish oil. Patients with PKU had significantly longer P100 latencies than 22 age-matched control subjects. After 3 months of LC-PUFA supplementation, VEP latencies improved significantly in PKU patients but did not change in 12 untreated healthy children. The authors conclude that omega-3 LC-PUFA are essential substrates for nervous system function even beyond infancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673596     DOI: 10.1212/wnl.57.8.1488

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  A randomized, placebo-controlled, double-blind trial of supplemental docosahexaenoic acid on cognitive processing speed and executive function in females of reproductive age with phenylketonuria: A pilot study.

Authors:  S H L Yi; J A Kable; M L Evatt; R H Singh
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2011-10-14       Impact factor: 4.006

2.  Omega-3 long-chain polyunsaturated fatty acids in older children.

Authors:  William C Heird
Journal:  J Pediatr       Date:  2007-05       Impact factor: 4.406

3.  Diet History Is a Reliable Predictor of Suboptimal Docosahexaenoic Acid Levels in Adult Patients with Phenylketonuria.

Authors:  T Bosdet; J Branov; C Selvage; M Yousefi; S Sirrs
Journal:  JIMD Rep       Date:  2015-03-03

4.  Dietary long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria: a randomized controlled trial.

Authors:  B Koletzko; T Sauerwald; H Demmelmair; M Herzog; U von Schenck; H Böhles; U Wendel; J Seidel
Journal:  J Inherit Metab Dis       Date:  2007-04-12       Impact factor: 4.982

Review 5.  Nutritional issues in treating phenylketonuria.

Authors:  François Feillet; Carlo Agostoni
Journal:  J Inherit Metab Dis       Date:  2010-02-12       Impact factor: 4.982

6.  A cross-sectional study of docosahexaenoic acid status and cognitive outcomes in females of reproductive age with phenylketonuria.

Authors:  Sarah H L Yi; Julie A Kable; Marian L Evatt; Rani H Singh
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

7.  Current Complementary and Alternative Therapies for Multiple Sclerosis.

Authors:  Allen C. Bowling; Thomas M. Stewart
Journal:  Curr Treat Options Neurol       Date:  2003-01       Impact factor: 3.598

8.  Phenylketonuria: nutritional advances and challenges.

Authors:  Marcello Giovannini; Elvira Verduci; Elisabetta Salvatici; Sabrina Paci; Enrica Riva
Journal:  Nutr Metab (Lond)       Date:  2012-02-03       Impact factor: 4.169

9.  Pre-attentive processing in children with early and continuously-treated PKU. Effects of concurrent Phe level and lifetime dietary control.

Authors:  Leo M J de Sonneville; Stephan C J Huijbregts; Robert Licht; Joseph A Sergeant; Francjan J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2011-05-04       Impact factor: 4.982

10.  Metabolomics of dietary fatty acid restriction in patients with phenylketonuria.

Authors:  Ulrike Mütze; Skadi Beblo; Linda Kortz; Claudia Matthies; Berthold Koletzko; Mathias Bruegel; Carmen Rohde; Joachim Thiery; Wieland Kiess; Uta Ceglarek
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.